Der skal gennemføres en langsigtet, dobbeltblind, placebokontrolleret undersøgelse som en del af forpligtelserne efter markedsføring (se bilag IV).
This Marketing Authorisation is subject to conditions considered essential for the safe and effective use of the medicinal product, which are that a long-term, double-blind, placebo controlled trial should be conducted as a post-marketing commitment (see Annexe IV).